Renaissance Technologies (RenTech)'s NBIX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 2.24 M shares of Neurocrine Biosciences, Inc. (NBIX) worth $317.53 M, representing 0.49% of the portfolio. First purchased in 2015-Q3, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in NBIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2020, adding 765,382 shares. Largest reduction occurred in Q1 2021, reducing 409,327 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -179,500 | Reduce 7.42% | 2.24 M | $141.83 |
| Q3 2025 | +51,900 | Add 2.19% | 2.42 M | $140.38 |
| Q2 2025 | -136,300 | Reduce 5.45% | 2.37 M | $125.69 |
| Q1 2025 | +13,300 | Add 0.53% | 2.5 M | $110.60 |
| Q4 2024 | -85,149 | Reduce 3.31% | 2.49 M | $136.50 |
| Q3 2024 | +106,400 | Add 4.31% | 2.57 M | $115.22 |
| Q2 2024 | +216,500 | Add 9.62% | 2.47 M | $137.67 |
| Q1 2024 | +263,100 | Add 13.23% | 2.25 M | $137.92 |
| Q4 2023 | +398,382 | Add 25.05% | 1.99 M | $131.76 |
| Q3 2023 | -53,238 | Reduce 3.24% | 1.59 M | $112.50 |
| Q2 2023 | -303,662 | Reduce 15.60% | 1.64 M | $0.09 |
| Q1 2023 | +333,400 | Add 20.66% | 1.95 M | $0.10 |
| Q4 2022 | +171,200 | Add 11.87% | 1.61 M | $0.12 |
| Q3 2022 | -6,559 | Reduce 0.45% | 1.44 M | $106.21 |
| Q2 2022 | +168,900 | Add 13.19% | 1.45 M | $97.48 |
| Q1 2022 | -143,541 | Reduce 10.08% | 1.28 M | $93.75 |
| Q4 2021 | +67,700 | Add 4.99% | 1.42 M | $85.17 |
| Q3 2021 | +113,241 | Add 9.11% | 1.36 M | $95.91 |
| Q2 2021 | -155,141 | Reduce 11.10% | 1.24 M | $97.32 |
| Q1 2021 | -409,327 | Reduce 22.65% | 1.4 M | $97.25 |
| Q4 2020 | -342,273 | Reduce 15.92% | 1.81 M | $95.85 |
| Q3 2020 | +664,700 | Add 44.77% | 2.15 M | $96.16 |
| Q2 2020 | +765,382 | Add 106.39% | 1.48 M | $122.00 |
| Q1 2020 | -19,790 | Reduce 2.68% | 719,382 | $86.55 |
| Q4 2019 | +735,272 | Add 18853.13% | 739,172 | $107.49 |
| Q3 2019 | -11,341 | Reduce 74.41% | 3,900 | $90.00 |
| Q2 2019 | -212,700 | Reduce 93.31% | 15,241 | $84.44 |
| Q1 2019 | +152,100 | Add 200.55% | 227,941 | $88.10 |
| Q4 2018 | +75,841 | New Buy | 75,841 | $71.41 |
| Q2 2018 | -162,341 | Sold Out | 0 | $0.00 |
| Q1 2018 | -224,900 | Reduce 58.08% | 162,341 | $82.93 |
| Q4 2017 | +387,241 | New Buy | 387,241 | $77.59 |
| Q4 2015 | -130,641 | Sold Out | 0 | $0.00 |
| Q3 2015 | +130,641 | New Buy | 130,641 | $39.79 |
Renaissance Technologies (RenTech)'s Neurocrine Biosciences Investment FAQs
Renaissance Technologies (RenTech) first purchased Neurocrine Biosciences, Inc. (NBIX) in Q3 2015, acquiring 130,641 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Neurocrine Biosciences, Inc. (NBIX) for 34 quarters since Q3 2015.
Renaissance Technologies (RenTech)'s largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q2 2020, adding 1,484,764 shares worth $181.14 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 2,238,797 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $317.53 M.
As of the Q4 2025 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.49% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Neurocrine Biosciences, Inc. (NBIX) was 2,574,546 shares, as reported at the end of Q3 2024.